SAVE THE DATE!
2021 HTRS Scientific Symposium
Registration is open for the 2021 HTRS Scientific Symposium, which has gone virtual and is now scheduled for March 10-12, 2021.
To register*, CLICK HERE
*Active HTRS members receive discounted registration as a benefit of membership. To join or renew your membership today, CLICK HERE. HTRS members, please check the Members-Only website page for your member code to use during registration.
HTRS will continue to be a comprehensive scientific meeting dedicated to continuing medical education and the advancement of clinical, translational, and basic science researched related to non-malignant blood disorders in both pediatric and adult medicine. Our target audience is:
- Clinicans and physician-scientists in pedatric and adult medicine, including related fields such as cardiology, pulmonology, and obstetrics/gynecology
- Medical students, trainees, and junior faculty
- Basic and translational scientists
- Nurses and nurse practitioners
- Physican assistants
- Any allied health professionals interested in hemostasis and/or thrombosis
- Industry colleagues
For full details, CLICK HERE.
We look forward to exploring hot topics in hemostasis and thrombosis, including COVID-19 and its impact on our field. Dynamic, lively scientific exchange in this collegial atmosphere can and will continue as we adapt to this “new normal.”
2021 HTRS Research Colloquium
The HTRS 2021 Research Colloquium is rescheduled for March 8-9, 2021 as a live, online pre-conference to the HTRS 2021 Scientific Symposium on March 10-12, 2021.
For important info for new registrants, previous registrants, and award recipients, CLICK HERE. Questions? Email [email protected].
It will be a dynamic meeting focused on professional development and networking in benign hematology for:
- Basic Scientists
- Translational Researchers
- Location: Pre-THSNA Summit 2020 at the Hyatt Regency Chicago
REGISTRATION LINK: Registration is still open! Visit this link to submit a new application and upload supporting documents before Friday, December 18, 2020 by 11:59 PM ET.
For complete details, CLICK HERE
2021 FWGBD Colloquium on Uterine Hemostasis
The Foundation for Women & Girls with Blood Disorders' (FWGBD - www.fwgbd.org) biennial colloquium on uterine hemostasis is scheduled for March 9, 2021 from 9:00 AM ET - 12 PM ET. It will convene leading faculty/researchers/clinicians to review our current understanding of the science and evidence-based practice related to the diagnosis and clinical management of abnormal uterine hemostasis.
The colloquium is complimentary for all HTRS Symposium attendees, and CME credits will be provided.
For full meeting agenda, CLICK HERE.
To register through the HTRS registration portal, CLICK HERE.
The educational goals for this meeting are:
- Review the state of the science with respect to normal uterine hemostasis
- Review the range of complications related to abnormal uterine hemostasis
- Describe and review the epidemiology and variability in phenotype regarding women with hemophilia
- Examine the full range of options for achieving uterine hemostasis in women with acute abnormal uterine bleeding, postpartum hemorrhage, and bleeding and clotting disorders including thrombotic microangiopathies
- Describe and underscore for target healthcare providers, the intersection of obstetrics/gynecology and hematology in the optimal care of these women and develop mechanisms for facilitating collaboration of these specialties.
Abstracts at ASH 2020
For an updated listing of HTRS members' accepted abstracts at ASH 2020 -- oral and poster presentations, as well as special interest sessions, please: CLICK HERE.
NHLBI News: Blueprint, Strategies and Tools for Future Factor VIII Inhibitor-Related Research
Factor VIII Inhibitor State of the Science Workshop Proceedings were published in the July 2019 edition of Hemophilia - Volume 24, Issue 4.
Abstracts from 2019 Symposium published in Haemophilia
The Abstracts from the HTRS/NASTH 2019 Scientific Symposium were published in Haemophilia, the official journal of HTRS.
Podcast: NHLBI Resources and Grants for Hematologists with Drs. DiMichele and Hoots
How to maximize research training and funding opportunities for non-malignant hematology and blood science investigators is the subject of this free podcast, in which Dr. Donna DiMichele and Dr. Keith Hoots of the National Heart, Lung, and Blood Institute (NHLBI) talk about NHLBI and National Institutes of Health resources and grants available to hematologists.
Join a Registry
The Children’s Hospital-Acquired Thrombosis (CHAT) Study
NHF: Research Project Funding Opportunities
The National Hemophilia Foundation (NHF) offers funding opportunities for bleeding disorders investigators at all career stages who are interested in inherited bleeding disorders research or clinical projects.
Application deadlines are approaching in February, March, April and May 2021. For a full listing of award opportunities, please CLICK HERE.
The Jeanne Marie Lusher Predoctoral Diversity Fellowship seeks research applicants from communities of color and/or those that are nationally underrepresented with the aim of increasing diversity in benign hematology. For more info, CLICK HERE.
Questions, Contact NHF's Research Department at [email protected].
National Institutes of Health Center for Scientific Review
The Center for Scientific Review (CSR) at the National Institutes of Health (NIH) offers two programs that could be valuable for HTRS members:
EARLY CAREER REVIEWER PROGRAM:
Early career scientists who would like review experience can apply to participate in the NIH Early Career Reviewer (ECR) Program. The goals of the ECR Program are to help early career scientists become more competitive as grant applicants through first-hand experience with peer review and to enrich and diversify CSR's pool of trained reviewers.
For more info or to apply to the ECR Program, please CLICK HERE
SCIENTIFIC SOCIETY- REVIEWER RECOMMENDATIONS PORTAL:
HTRS members are invited to recommend scientists to serve as grant reviewers through the NIH Review Recommendation portal. Reviewers should be scientists who are generally willing to serve as reviewers and are seen as experts, with integrity, in their field. They should have an active research program, extramural funding, and not currently be a standing member of an NIH study section or advisory council. The NIH is encouraging HTRS to recommend productive scientists from diverse backgrounds and career stages – e.g. assistant, associate, and full professors.
If you would like HTRS to nominate you or a colleague as an NIH reviewer, please email [email protected] for more info.
2020 HTRS/ATHN Dataset Research Engagement and ATHN Mentorship ("DREAM") Award: Deadline has passed
Together, we're helping turn dreams into reality. The DREAM Award is offered through the collaboration of HTRS and ATHN and supported by an independent medical educational grant from Takeda. Key details:
- Applicants residing in the U.S. and working at U.S.-based, ATHN-affiliated HTCs were eligible to apply for a 2020 DREAM Award.
- The award offers funding of $50,000 USD per recipient for projects lasting up to one year and $100,000 USD per recipient for projects lasting up to two years.
2020 HTRS Student Research Awards: Deadline has passed
The deadline has passed for the Hemostasis and Thrombosis Research Society (HTRS) Student Research Award, an 8- to 10-week program for medical, PhD, MD/PhD, or PharmD students working on targeted research projects in hemostasis and thrombosis. Proposed projects may be lab-based, clinical or epidemiologic in design. The program includes a $5,000 award stipend plus a $2,000 travel allowance, collaboration with a research mentor, and a presentation at a 2021 professional meeting. Watch for more details late 2020 for next year's program.
Dr. Anthony Fauci praises HTRS Member Lisa Baumann Kreuziger for her work on national COVID-19 panel
Dr. Lisa Baumann Kreuziger, MD, MS, Medical Director at the Versiti Blood Center of Wisconsin, was praised in a personal letter of gratitude from White House advisor and director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci.
A hematology expert, Dr. Baumann Kreuziger is serving on a national COVID-19 panel that recommends the best treatment options for people with the virus. The guidelines have been developed to inform clinicians how to care for patients with COVID-19, she says.
"You responded in an exceptional way and worked tirelessly to develop an outstanding initial set of guidelines in two weeks," wrote Dr. Fauci. "In the first week after their release on April 21, there were more than 1 million page views, highlighting the importance of your work. Thank you again for your contributions to this panel, for your outstanding work in caring for patients and for all the additional ways you are helping to respond to this pandemic during this most extraordinary time."
Says Dr. Baumann Kreuziger, "I was honored and humbled to be part of a group of experts to establish treatment recommendations. The guidelines have provided a review of evidence on which doctors can treat patients and develop research."